by Roger Longman
Since the beginning of the decade, Roche has been the single most successful investment in Big Pharma. And the...
Even though Roche has been the single most successful investment in Big Pharma--because Roche has been the single most successful investor in Big Pharma--productivity over the past few years was slowed by leadership bottlenecks, misalignment among functions, and roadblocks to creativity. Roche's brand-new research boss, Lee Babiss, says a new decentralized structure and a more aggressive out-partnering strategy is designed to address the issues, manage risk, and spur post-2015 growth
by Roger Longman
Since the beginning of the decade, Roche has been the single most successful investment in Big Pharma. And the...
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
After 10 years of promised investment following its Nobel Prize for iPS cell research, Japan is cautiously narrowing regulations around the conditional approval of cell therapies and cutting some reimbursement prices. Commercial success remains mixed and some products have been withdrawn from the market.
Mary Jane Hinrichs, Ipsen’s head of early development, talks to In Vivo about getting ahead of the competition by securing deals for candidates before they enter Phase I trials.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.
Launching In Vivo’s oncology therapeutic review series, this first instalment provides a data-led primer on the global cancer landscape. Future instalments will explore market dynamics, pipeline evolution and the innovations set to define oncology therapeutics through 2032.